Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Vaccines01:30

Cancer Vaccines

568
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
568
Vaccinations01:51

Vaccinations

46.5K
Overview
46.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early Efficacy and Exploratory Biomarker Data of Bel-sar in Patients with Intermediate-risk and High-risk Non-muscle-invasive Bladder Cancer.

European urology open science·2026
Same author

Temporal trends in anal HPV infection among men who have sex with men attending sexual health clinics in three United States cities, 2018-2024.

Sexually transmitted diseases·2026
Same author

Immunization with Herpes Simplex Virus Nanoparticles Targeting Both Attachment and Fusion Protect Against Infection.

bioRxiv : the preprint server for biology·2026
Same author

Exceeding expectations: factors contributing to the potency of human papillomavirus vaccines.

The Lancet. Microbe·2026
Same author

Decreases in Human Papillomavirus Vaccine Types 16 and 18 in Cervical Precancers: HPV-IMPACT, 2008 to 2019.

Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology·2026
Same author

Noninferiority of One HPV Vaccine Dose to Two Doses.

The New England journal of medicine·2025
Same journal

Diverse genetic lineages spreading across healthcare and community boundaries underlie extended-spectrum cephalosporin-resistant Enterobacterales (ESCrE) colonization burden in Botswana.

The Journal of infectious diseases·2026
Same journal

Retraction of: Tracking Plasmodium knowlesi Through Fecal DNA for Monitoring Zoonotic Transmission in Wild Macaques Across Southeast and South Asia.

The Journal of infectious diseases·2026
Same journal

Can malaria induce loss of vaccine immunity.

The Journal of infectious diseases·2026
Same journal

NET-inducing ability of Cutibacterium acnes clinical isolates is associated with pathogenicity in acne vulgaris.

The Journal of infectious diseases·2026
Same journal

Optimizing the Use of Proviral DNA HIV Drug Resistance Testing: Clinical Applications and Cautions.

The Journal of infectious diseases·2026
Same journal

Monitoring HLA-A2-restricted T cell responses and BCLA-specific serostatus during human latent Toxoplasma gondii infection suggests the implication of CD8+ T cells in parasite containment.

The Journal of infectious diseases·2026
See all related articles

Related Experiment Video

Updated: Oct 18, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.6K

Human Papillomavirus Vaccines.

Lauri E Markowitz1, John T Schiller2

  • 1National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.

The Journal of Infectious Diseases
|September 30, 2021
PubMed
Summary
This summary is machine-generated.

Human papillomavirus (HPV) vaccines are highly effective, preventing infections from sexually transmitted agents without inducing mucosal immunity. Real-world data confirms their safety and impact, driving ambitious disease reduction goals.

Keywords:
HPVHPV vaccinehuman papillomavirus

More Related Videos

Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.3K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.7K

Related Experiment Videos

Last Updated: Oct 18, 2025

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus
13:41

Use of Interferon-γ Enzyme-linked Immunospot Assay to Characterize Novel T-cell Epitopes of Human Papillomavirus

Published on: March 8, 2012

12.6K
Expression and Purification of Virus-like Particles for Vaccination
06:17

Expression and Purification of Virus-like Particles for Vaccination

Published on: June 2, 2016

22.3K
RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma
10:26

RNAscope for In situ Detection of Transcriptionally Active Human Papillomavirus in Head and Neck Squamous Cell Carcinoma

Published on: March 11, 2014

27.7K

Area of Science:

  • Immunology
  • Vaccinology
  • Public Health

Background:

  • Human papillomavirus (HPV) vaccines represent a significant advancement in preventing sexually transmitted infections.
  • These vaccines are the first to target a mucosatropic infectious agent without requiring mucosal immunity induction.
  • Current vaccines utilize virus-like particles derived from the L1 major capsid protein.

Purpose of the Study:

  • To review the development, implementation, and impact of HPV vaccines.
  • To highlight the effectiveness and safety of HPV vaccines based on real-world data.
  • To discuss the evolution of vaccination policies and future disease reduction goals.

Main Methods:

  • Review of clinical trial data and post-licensure surveillance from national immunization programs.
  • Analysis of vaccine efficacy, safety, and population-level impact.
  • Examination of vaccination policy trends, including age and gender targeting.

Main Results:

  • HPV vaccines, first licensed in 2006, target HPV-16 and HPV-18, responsible for most HPV-attributable cancers.
  • As of 2020, over 100 countries have integrated HPV vaccines into national immunization programs.
  • Vaccination policies have expanded to include adolescent boys, with confirmed efficacy and safety in real-world settings.

Conclusions:

  • HPV vaccines have demonstrated dramatic effectiveness and safety, validating prelicensure trial findings.
  • The success of HPV vaccination programs has spurred interest in achieving ambitious goals for HPV-related disease reduction.
  • Continued monitoring and policy evolution are crucial for maximizing the public health benefits of HPV vaccination.